What question did this study set out to answer?

This research aims to evaluate the effectiveness of transcatheter arterial chemoembolization combined with immunotherapy for advanced liver cancer.

Efficacy of TACE combined with targeted immunotherapy in the treatment of advanced liver cancer

View Full Paper

Ask AI

Bookmark

Authors

Retrospective trial investigates combination therapy's impact on tumor markers and survival in liver cancer patients, suggesting improved outcomes.

This research aims to evaluate the effectiveness of transcatheter arterial chemoembolization combined with immunotherapy for advanced liver cancer.
Retrospective analysis of 115 intermediate-advanced liver cancer patients treated from June 2021 to June 2024.
Patients divided into conventional TACE group (n=57) and TACE combined with immunotherapy group (n=58).
Propensity score matching was performed to control confounding factors.
Combined group showed a higher objective response rate (P < 0.05) and lower tumor marker levels (P < 0.001) compared to conventional group.
One-year cumulative survival rate was significantly higher in the combined group (P < 0.05).
Combination therapy was identified as an independent protective factor for survival (HR = 0.520, P = 0.012).

Xie et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective trial investigates combination therapy's impact on tumor markers and survival in liver cancer patients, suggesting improved outcomes.